These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25749520)

  • 1. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules.
    Luo Q; Zhang Y; Wang N; Jin G; Jin H; Gu D; Tao X; Huo X; Ge T; Cong W; Wang C; Qin W
    Oncotarget; 2015 Mar; 6(9):6989-99. PubMed ID: 25749520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
    J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling.
    Nam SW; Park JY; Ramasamy A; Shevade S; Islam A; Long PM; Park CK; Park SE; Kim SY; Lee SH; Park WS; Yoo NJ; Liu ET; Miller LD; Lee JY
    Hepatology; 2005 Oct; 42(4):809-18. PubMed ID: 16175600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
    Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
    Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
    DU JL; Wei LX; Wang YL
    Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.
    Di Tommaso L; Destro A; Seok JY; Balladore E; Terracciano L; Sangiovanni A; Iavarone M; Colombo M; Jang JJ; Yu E; Jin SY; Morenghi E; Park YN; Roncalli M
    J Hepatol; 2009 Apr; 50(4):746-54. PubMed ID: 19231003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
    Luo Q; Wang C; Jin G; Gu D; Wang N; Song J; Jin H; Hu F; Zhang Y; Ge T; Huo X; Chu W; Shu H; Fang J; Yao M; Gu J; Cong W; Qin W
    Carcinogenesis; 2015 Oct; 36(10):1201-12. PubMed ID: 26249360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification.
    Roncalli M; Roz E; Coggi G; Di Rocco MG; Bossi P; Minola E; Gambacorta M; Borzio M
    Hepatology; 1999 Nov; 30(5):1174-8. PubMed ID: 10534338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
    Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
    Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array.
    Okamura Y; Nomoto S; Kanda M; Li Q; Nishikawa Y; Sugimoto H; Kanazumi N; Takeda S; Nakao A
    Cancer Lett; 2010 Mar; 289(2):170-7. PubMed ID: 19733004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
    Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
    Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
    Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
    Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dysplastic nodule of liver versus early hepatocellular carcinoma: a clinicopathologic and prognostic study].
    Chen L; Tan Y; Zeng H; Hou Y; Xu J; Zhao J; Ji Y
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):301-6. PubMed ID: 25030861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
    Kowalik MA; Puliga E; Cabras L; Sulas P; Petrelli A; Perra A; Ledda-Columbano GM; Morandi A; Merlin S; Orrù C; Sanchez-Martin C; Fornari F; Gramantieri L; Parri M; Rasola A; Bellomo SE; Sebastian C; Follenzi A; Giordano S; Columbano A
    J Hepatol; 2020 Jun; 72(6):1159-1169. PubMed ID: 31954205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular dysplastic nodules.
    Roncalli M; Borzio M; Di Tommaso L
    Ann Ital Chir; 2008; 79(2):81-9. PubMed ID: 18727269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
    Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
    Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging.
    Gatto A; De Gaetano AM; Giuga M; Ciresa M; Siciliani L; Miele L; Riccardi L; Pizzolante F; Rapaccini GL; Gasbarrini A; Giuliante F; Vecchio FM; Pompili M; Bonomo L
    Abdom Imaging; 2013 Aug; 38(4):736-44. PubMed ID: 22986351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.